Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathy.

The Journal of clinical investigation·2026
Same author

Inhibition of p65 NF-κB enhances production of galactose-deficient IgA1 through suppression of <i>C1GALT1</i> and SP1 in plasmablast-like cell subpopulations.

bioRxiv : the preprint server for biology·2026
Same author

Perspectives and Practices in Pediatric to Adult Healthcare Transition in Kidney Transplantation: An American Society of Transplantation (AST) Member Survey.

Pediatric transplantation·2026
Same author

Corticosteroid Therapy and Long-Term Outcomes of Post-Infectious Inflammatory Syndrome in Non-HIV Immunosuppressed Cryptococcal Meningitis: A Multicenter Case Series.

The Journal of infectious diseases·2026
Same author

Topography of the HLA-A protein enforces shared and convergent immunodominant B cell and antibody alloresponses in transplant recipients.

Immunity·2025
Same author

Proteomic Analysis of Circulating IgA1-Containing Immune Complexes in Patients with IgA Nephropathy.

Kidney international reports·2025
Same journal

Current Options for Kidney Protection: Are Renin-Angiotensin System Inhibitors Still Relevant?

Seminars in nephrology·2026
Same journal

Proposed Role for Quantitative Podocyturia as a Clinical Marker of Systemic Endothelial Injury: Implications for Cardiovascular Disease and Longevity.

Seminars in nephrology·2026
Same journal

Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?

Seminars in nephrology·2026
Same journal

From Nephron Number to Global Health.

Seminars in nephrology·2026
Same journal

Chronic Kidney Disease Progression Mechanisms: Why They Matter in an Era of Novel Kidney Protective Therapies.

Seminars in nephrology·2026
Same journal

Of Diuretics, Transporters, and Mechanisms of Hypertension.

Seminars in nephrology·2026
See all related articles

Related Experiment Video

Updated: May 22, 2025

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.8K

Post-transplant IgA Nephropathy.

Song C Ong1, Bruce A Julian1

  • 1Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA.

Seminars in Nephrology
|March 14, 2025
PubMed
Summary
This summary is machine-generated.

Immunoglobulin A (IgA) nephropathy often recurs after kidney transplants, impacting graft survival. Research is exploring biomarkers and autoimmune mechanisms for better post-transplant IgA nephropathy management.

Keywords:
Autoimmune diseaseIgA nephropathyrecurrencetransplantationtreatment

More Related Videos

Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET
17:13

Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET

Published on: April 28, 2013

16.9K
Mouse Kidney Transplantation: Models of Allograft Rejection
16:15

Mouse Kidney Transplantation: Models of Allograft Rejection

Published on: October 11, 2014

20.5K

Related Experiment Videos

Last Updated: May 22, 2025

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.8K
Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET
17:13

Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET

Published on: April 28, 2013

16.9K
Mouse Kidney Transplantation: Models of Allograft Rejection
16:15

Mouse Kidney Transplantation: Models of Allograft Rejection

Published on: October 11, 2014

20.5K

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation

Background:

  • Immunoglobulin A (IgA) nephropathy is a leading cause of kidney failure globally.
  • Kidney transplantation is the primary treatment for end-stage renal disease due to IgA nephropathy.
  • Recurrence of IgA nephropathy post-transplant is common and reduces graft longevity.

Purpose of the Study:

  • To review risk factors, clinical presentation, and management strategies for post-transplant IgA nephropathy.
  • To highlight the need for biomarker validation in the context of kidney transplantation.
  • To explore the potential of novel autoimmune-targeted therapies for recurrent IgA nephropathy.

Main Methods:

  • Literature review of studies on IgA nephropathy recurrence after kidney transplantation.
  • Analysis of recipient and donor factors associated with recurrence.
  • Examination of the role of immunosuppression in modifying disease expression.
  • Review of current and emerging treatment strategies.

Main Results:

  • Recipient and donor characteristics influence IgA nephropathy recurrence risk, though findings vary across studies.
  • Immunosuppression regimens can alter the clinical presentation of post-transplant IgA nephropathy.
  • Biomarkers identified in native IgA nephropathy require validation in transplant settings.
  • Current treatments for recurrent IgA nephropathy primarily rely on supportive care and evidence from native kidney disease.

Conclusions:

  • Understanding autoimmune mechanisms in IgA nephropathy offers potential therapeutic targets for post-transplant recurrence.
  • Further research is needed to validate biomarkers and refine treatment protocols for recurrent IgA nephropathy in kidney transplant recipients.
  • Optimizing immunosuppression and exploring new treatments are crucial for improving allograft survival in IgA nephropathy patients.